Back to Search
Start Over
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele
- Source :
- Proceedings of the National Academy of Sciences of the United States. Sept 26, 2000, Vol. 97 Issue 20, 10917
- Publication Year :
- 2000
-
Abstract
- NY-ESO-1 elicits frequent antibody responses in cancer patients, accompanied by strong [CD8.sup.+] T cell responses against HLA-A2-restricted epitopes. To broaden the range of cancer patients who can be assessed for immunity to NY-ESO-1, a general method was devised to detect T cell reactivity independent of prior characterization of epitopes. A recombinant adenoviral vector encoding the full cDNA sequence of NY-ESO-1 was used to transduce CD8-depleted peripheral blood lymphocytes as antigen-presenting cells. These modified antigen-presenting cells were then used to restimulate memory effector cells against NY-ESO-1 from the peripheral blood of cancer patients. Specific [CD8.sup.+] T cells thus sensitized were assayed on autologous B cell targets infected with a recombinant vaccinia virus encoding NY-ESO-1. Strong polyclonal responses were observed against NY-ESO-1 in antibody-positive patients, regardless of their HLA profile. Because the vectors do not cross-react immunologically, only responses to NY-ESO-1 were detected. The approach described here allows monitoring of [CD8.sup.+] T cell responses to NY-ESO-1 in the context of various HLA alleles and has led to the definition of NY-ESO-1 peptides presented by HLA-Cw3 and HLA-Cw6 molecules.
Details
- ISSN :
- 00278424
- Volume :
- 97
- Issue :
- 20
- Database :
- Gale General OneFile
- Journal :
- Proceedings of the National Academy of Sciences of the United States
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.67130290